Enzon Pharmaceuticals, Inc. Price & Performance (ENZN)

Novo Nordisk’s oral semaglutide, Rybelsus 14 mg, cut major cardiovascular event risk by 14% in type 2 diabetes patients with cardiovascular or chronic kidney disease, according to the SOUL trial. The findings, presented at the ACC conference and published in a leading journal, prompted Novo Nordisk to seek label expansion.1234

Data from the SOUL trial reveal that Rybelsus 14 mg not only reduces cardiovascular events in high-risk diabetes patients but also maintains a safety profile consistent with prior studies. Novo Nordisk’s label extension application is now under FDA review, with a decision expected later this year.34

A secondary SOUL trial analysis showed Rybelsus’ cardiovascular benefits were consistent regardless of patients’ use of SGLT2 inhibitors. The trial’s results reinforce the drug’s role in broader metabolic and cardiovascular care, supporting its potential as a frontline therapy for complex diabetes cases.42